Bank of America just raised its EUR/USD forecast
Allison C. Hoffman, General Counsel and Secretary of Phreesia, Inc. (NYSE:PHR), a $1.4 billion healthcare technology company that's currently trading near $24 per share, has recently sold shares of the company's common stock, according to a recent filing with the Securities and Exchange Commission. According to InvestingPro data, while the company isn't currently profitable, analysts expect positive earnings this year. The transactions occurred on April 8 and April 9, 2025, with a total sale value of $252,777.
On April 8, Hoffman sold 3,681 shares at prices ranging from $23.00 to $23.995 per share, totaling $86,354. Additionally, 2,343 shares were sold at prices between $24.00 and $24.915 per share, amounting to $57,335. On April 9, she sold another 4,696 shares at a price of $23.23 per share, totaling $109,088.
These transactions were part of the company's mandatory sell-to-cover policy to cover tax withholding obligations related to restricted stock units. The April 9 sale was executed under a Rule 10b5-1 trading plan adopted by Hoffman in September 2024. Following these sales, Hoffman holds 139,134 shares of Phreesia.
In other recent news, Phreesia Inc . has garnered attention following its fourth-quarter earnings and subsequent analyst assessments. Jefferies raised the company's price target from $28.00 to $32.00, maintaining a Buy rating. The decision was influenced by Phreesia's financial model reassessment and management's comments, highlighting operational leverage and a strategic shift towards Network Solutions. KeyBanc Capital Markets also reiterated an Overweight rating with a $30.00 target, noting significant margin improvements and the potential for continued growth in the Network Solutions sector. Raymond (NSE:RYMD) James maintained an Outperform rating with a $30.00 price target, emphasizing Phreesia's strategic focus on free cash flow and profitability. Meanwhile, DA Davidson reaffirmed a Buy rating with a $36.00 price target, citing Phreesia's consistent performance and value addition in the U.S. healthcare services sector. The firm's analysis suggests Phreesia's stock is undervalued, trading at a lower EBITDA multiple than peers. These recent developments reflect a positive outlook from analysts, who see potential in Phreesia's growth trajectory and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.